Aardvark Therapeutics (NASDAQ:AARD) Given New $26.00 Price Target at Bank of America

Aardvark Therapeutics (NASDAQ:AARD) had its target price increased by Bank of America from $22.00 to $26.00 in a report released on Thursday, Marketbeat reports. Bank of America currently has a buy rating on the stock.

Several other equities research analysts also recently weighed in on the stock. Cantor Fitzgerald assumed coverage on shares of Aardvark Therapeutics in a research report on Monday, March 10th. They issued an “overweight” rating and a $50.00 target price for the company. Royal Bank of Canada began coverage on Aardvark Therapeutics in a report on Monday, March 10th. They set an “outperform” rating and a $21.00 target price on the stock. Finally, Morgan Stanley began coverage on Aardvark Therapeutics in a report on Monday, March 10th. They issued an “overweight” rating and a $29.00 price target for the company.

Aardvark Therapeutics Trading Down 13.0 %

Aardvark Therapeutics stock opened at $7.74 on Thursday. Aardvark Therapeutics has a 52 week low of $7.74 and a 52 week high of $19.58.

Insider Buying and Selling at Aardvark Therapeutics

In other news, CEO Tien-Li Lee bought 16,542 shares of the firm’s stock in a transaction on Friday, February 14th. The stock was purchased at an average price of $16.00 per share, for a total transaction of $264,672.00. Following the transaction, the chief executive officer now owns 1,496,175 shares in the company, valued at approximately $23,938,800. This trade represents a 1.12 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Nelson Sun acquired 10,000 shares of the firm’s stock in a transaction that occurred on Friday, February 14th. The stock was acquired at an average cost of $16.00 per share, with a total value of $160,000.00. Following the completion of the acquisition, the chief financial officer now directly owns 99,484 shares in the company, valued at approximately $1,591,744. This represents a 11.18 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

About Aardvark Therapeutics

We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We target biological pathways associated with alleviating hunger that we believe have the potential to deliver transformative outcomes for patients.